

# A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

NCT06733935

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Nkarta, Inc.
<b>Enrollment</b>	144 participants

## Key Eligibility Criteria

---

### Inclusion (31)

- Age e18 and d70
- For participants taking corticosteroids, the prednisone (or equivalent) dose must be d40 mg/day at 6 weeks prior to Screening and stable for e 14 days before start of Screening
- For subjects on immunosuppressives or immunomodulators (other than corticosteroids), all doses must be stable for e 4 weeks prior to Screening
- SSc:
- Meets the 2013 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria for SSc
- ... and 26 more (see full listing online)

### Exclusion (40)

- eGFR < 45 ml/min/1.73m<sup>2</sup>
- Currently requiring renal dialysis or expected to require dialysis during the study period
- Previous solid organ or hematopoietic cell transplant or planned transplant within study treatment period
- Congenital or acquired immunodeficiency resulting in severe infection or those receiving chronic immunoglobulin replacement therapy
- Liver disease or dysfunction, including cirrhosis and/or bilirubin e 3 times the upper limit of normal
- ... and 35 more (see full listing online)

## Locations (15 total)

---

Nkarta Investigational Site, Orange, California, United States  
Nkarta Investigational Site, Miami, Florida, United States  
Nkarta Investigational Site, Plantation, Florida, United States  
... and 12 more locations